Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.
Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out.
Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.
A proposed amendment in Mexican law needs to be implemented urgently in order to adapt legislation to include provisions in accordance with the UPOV Convention, as Luz Flores of Uhthoff, Gómez Vega & Uhthoff reports.
A former Johnson & Johnson IP counsel and a retired judge are among the speakers at Life Sciences IP Due Diligence, on November 29 and 30 in Boston, as LSIPR finds out.
Costa Rica has released new rules for the clinical investigation of adult stem cells, as María del Pilar López and Esteban Monge of Zürcher Lawyers report.
Patenting antibodies across different jurisdictions can be a difficult task, as Kathy Coulter, senior IP counsel at Bristol-Myers Squibb, tells LSIPR.
While personalised medicine is a challenging area for drug developers, there are a number of potential solutions, as LSIPR finds out.
American biotech 3Scan is combining robotics with machine learning and automation to offer microscopy services for the 3D analysis of cells, tissues, and organs. LSIPR met general counsel Nada Rastad to hear about some of the patenting challenges.
Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.